SYNLOGIC, INC. Deferred Tax Assets, Operating Loss Carryforwards
SYNLOGIC, INC. (SYBX) had Deferred Tax Assets, Operating Loss Carryforwards of $108.89 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $108.89M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $102.14M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $87.40M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $81.80M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $108.89M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $102.14M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $87.40M 10-K · filed 2025-03-06 | |
| 2022-12-31 | $81.80M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $76.80M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $61.18M 10-K · filed 2022-03-17 | |
| 2019-12-31 | $46.36M 10-K · filed 2021-03-25 | |
| 2018-12-31 | $33.27M 10-K · filed 2020-03-12 | |
| 2017-12-31 | $21.25M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $11.48M 10-K · filed 2018-03-20 | $27.52M 10-K · filed 2017-03-15 |
| 2015-12-31 | $19.56M 10-K · filed 2017-03-15 | |
| 2014-12-31 | $12.41M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |